The Trump administration has initiated a Section 232 investigation into medical equipment, increasing tariff uncertainty for medtech companies. Despite 70% of medical devices used in the U.S. being domestically produced, industry group Advamed is advocating for tariff exemptions. The investigation encompasses various medical products, and analysts anticipate that any new tariffs could lead companies to pass costs to customers or increase U.S. manufacturing over time. However, the timeline for potential tariff implementation may not begin until summer 2026.

Source: https://www.supplychaindive.com/news/section-232-tariff-uncertainty-medtech/761260/